Sub Categories

Search

Newsletter

Amyloid beta-protein (1-40) ELISA Kit Maximize

Amyloid beta-protein (1-40) ELISA Kit

Human Amyloid beta-protein ELISA Kit (1-40) (EK-018-01) is a quantitative procedure for analysis in-vitro levels of human amyloid beta protein (1-40).

More details

EK-018-01

96 wells

£ 470.00

Human Amyloid beta-protein ELISA Kit (1-40)

Specificity : Human
Sensitivity : 0.625 ng/ml
Linear Range: 0.78-50.0 ng/ml
Assay Range : 0.01-100ng/ml
Size: 96 tests.

Reagents Supplied:
- Primary antibody (rabbit anti-peptide IgG)(1 vial).
- 2N HCl (15ml).
- Standard peptide (1 vial).
- Streptavidin-horseradish peroxidase (SA-HRP)(30μl).
- Substrate solution (TMB) (12ml).
- 96 well immunoplate (1 plate).
- 20x assay buffer concentrate (50ml).
- Positive control (2 vials).
- Acetate plate sealer (APS), (3 pieces).
- Biotinylated peptide (1 vial).
- Assay diagram (1 sheet).
- General protocol (1 book).

Intended Use:
Human Amyloid beta protein ELISA is a method that can be used to in-vitro quantitatively detect levels of human amyloid beta protein (1-40) using samples of  plasma, serum, culture media, urine, CSF and various other biological fluids.

Cross Reactivity:
Amyloid beta protein (1-40) 100%.
Amyloid beta protein (1-42)  0%.

Background:
Amyloid beta (Aβ) is transmembrane glycoprotein whose function has not been determined, however it is known to be made through the sequential cleavage of the amyloid precursor protein (APP). It is known to be intrinsically unstructured, i.e. it acquires no unique tertiary fold but instead populates a set of structures in a solution. The gene for precursor is located on chromosome 21 and is found to be linked to Alzheimer's disease, since the main component of amyloid plaques has been discovered in the brains of Alzheimer patients. Also, patients with Down's syndrome (trisomy 21) have a very high incidence of Alzheimer's disease.

References
1. J. Neurochem. (1988) 51 (2): 648-51. Differences between vascular and plaque core amyloid in Alzheimer's disease. Prelli F, et al.
2. BMC Genomics (2013)14 (1): 290. Origins of amyloid-beta. Sarkar IN and Tharp G.
3. Neurology (2003) 61 (2): 199-205. Mild hypercholesterolemia is an early risk factor for the development of Alzheimer amyloid pathology. Pappolla MA, et al.
4. Neurobiol Dis (2000) 20007 (4): 321-331. Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Refolo LM, et al.
5. Am. J. Pathol. (1999) 155 (3): 853-62. Soluble Amyloid β Peptide Concentration as a Predictor of Synaptic Change in Alzheimer's Disease. Lue LF, et al.
6. Medical Principles and Practice (2014) 24: 1-10. Amyloid-Beta: A Crucial Factor in Alzheimer’s Disease. Sadigh-Eteghad S, et al.

Please contact us if you require the detailed protocol insert.

Special Offers